RET fusion
Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene RET
Variant fusion
Impact List fusion
Protein Effect unknown
Gene Variant Descriptions RET fusion indicates a fusion of the RET gene, but the fusion partner is unknown.
Associated Drug Resistance
Category Variants Paths

RET mutant RET rearrange RET fusion

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04320888 Phase II Selpercatinib Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Active, not recruiting USA | AUS 1
NCT06644768 Phase Ib/II Pembrolizumab DS-3201b + Pembrolizumab A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations Active, not recruiting USA | BRA | ARG 2
NCT05379595 Phase Ib/II Amivantamab-vmjw Amivantamab-vmjw + Fluorouracil + Irinotecan + Leucovorin Amivantamab-vmjw + Fluorouracil + Leucovorin + Oxaliplatin A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (OrigAMI-1) Recruiting USA | ITA | ESP | DEU | CAN | BEL 5
NCT04759911 Phase II Selpercatinib Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Active, not recruiting USA 0
NCT04085315 Phase I Alisertib + Osimertinib Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer Completed USA 0
NCT02587650 Phase II Ceritinib Capmatinib Regorafenib Entrectinib Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma Terminated USA 0
NCT04484142 Phase II Datopotamab deruxtecan Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) Completed USA | NLD | ITA | HUN | FRA | ESP | DEU 3
NCT03639714 Phase Ib/II GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab A Study of a Personalized Neoantigen Cancer Vaccine Completed USA | AUS 0
NCT06275360 Phase II Nivolumab Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel Repositioning Immunotherapy in VetArans With Lung Cancer (RIVAL) Recruiting USA 0
NCT06495125 Phase II Defactinib + Nivolumab + RO5126766 Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer Recruiting USA 0
NCT02193152 Phase I Pazopanib Pazopanib in Molecularly Selected Patients With Advanced NSCLC Terminated USA 0
NCT04161391 Phase Ib/II TPX-0046 Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations Terminated USA 1
NCT02299141 Phase I Nintedanib Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer Completed USA 0
NCT07586202 Phase II Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Carboplatin + Pemetrexed Disodium A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC (AmiNA) Recruiting USA | ESP | CAN 3
NCT05788926 Phase I TG6050 A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir) Terminated FRA 0
NCT05200481 Phase II Brigatinib + Carboplatin + Pemetrexed Disodium Brigatinib Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) (MP-ALK) Active, not recruiting FRA 0
NCT05635708 Phase II Nab-paclitaxel Cisplatin BGB-15025 + Tislelizumab BGB-A445 + Tislelizumab Paclitaxel Tislelizumab Carboplatin Pemetrexed Disodium LBL-007 + Tislelizumab A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer Completed USA | ROU | ITA | FRA | ESP | CAN | BRA | AUS 7
NCT07450183 Phase II Cemiplimab Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 Not yet recruiting USA 0
NCT07355205 Phase Ib/II Ipilimumab + Nivolumab + Nogapendekin alfa inbakicept First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN) Recruiting USA 0
NCT05064280 Phase II Lenvatinib + Pembrolizumab Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases Recruiting USA 0
NCT05443126 Phase Ib/II Carboplatin + EP0031 + Pemetrexed Disodium Cisplatin + EP0031 + Pemetrexed Disodium A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies Recruiting USA | POL | ITA | GBR | FRA | ESP | DEU 1
NCT07405190 Phase II Ivonescimab Carboplatin + Ivonescimab + Pemetrexed Disodium Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC Recruiting USA 0
NCT05715229 Phase II Carboplatin + Paclitaxel Carboplatin + Pemetrexed Disodium Ipilimumab + Nivolumab Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy (G360-IIT) Terminated USA 0
NCT05781308 Phase II Atezolizumab + Bevacizumab + Paclitaxel Bevacizumab + Paclitaxel Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy (ADAPTABLE) Active, not recruiting FRA 0
NCT05668962 Phase II Selpercatinib Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC Unknown status USA 0
NCT07889232 Phase Ib/II Carboplatin + Pembrolizumab + Pemetrexed Disodium + Tocilizumab Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer (TOCI) Not yet recruiting USA 0
NCT01639508 Phase II Cabozantinib Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity Recruiting USA 0
NCT04581824 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Dostarlimab-gxly + Pemetrexed Disodium Carboplatin + Dostarlimab-gxly + Pemetrexed Disodium Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Terminated USA | ROU | POL | ITA | FRA | ESP | DEU | BRA | ARG 3
NCT04984811 Phase II Atezolizumab + NT-I7 NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC Terminated USA 0
NCT05401786 Phase II Cemiplimab Ipilimumab Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC (RAD-IO) Active, not recruiting NLD 0
NCT06908993 Phase III Vinorelbine Pemetrexed Disodium Tepotinib Pembrolizumab Bevacizumab + Paclitaxel Paclitaxel Docetaxel Nivolumab Atezolizumab Gemcitabine Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated (COMET) Recruiting FRA 0
NCT07680764 Phase II BMS-986340 + BNT327 BNT327 A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Recruiting USA | ROU | ITA | GBR | FRA | ESP | DEU | BRA | AUS | ARG 2
NCT07699328 Phase Ib/II VRN110755 A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (REACH-EGFR) Recruiting FRA | ESP | CAN | AUS 6
NCT07020065 Phase II Carboplatin + Cemiplimab + Gemcitabine Carboplatin + Cemiplimab + Pemetrexed Disodium Cemiplimab Carboplatin + Cemiplimab + Paclitaxel Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% Recruiting CHE 0
NCT04892953 Phase II Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Nab-paclitaxel Carboplatin + Durvalumab + Gemcitabine Durvalumab Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy Recruiting USA 0
NCT04862780 Phase Ib/II BLU-945 BLU-945 + Osimertinib (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC Terminated USA | NLD | GBR | FRA | ESP | CAN 4
NCT03780517 Phase I Zeteletinib Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors Completed USA | FRA | ESP | BEL 3
NCT07365319 Phase II Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + EIK1001 + Pembrolizumab + Pemetrexed Disodium Carboplatin + EIK1001 + Nab-paclitaxel + Pembrolizumab Carboplatin + EIK1001 + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + EIK1001 + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. (TeLuRide-008) Recruiting USA | POL | GRC | ESP | DEU | BRA | BEL | AUT | AUS 2
NCT07468071 Phase Ib/II JDQ443 JDQ443 + TNO155 Cetuximab + JDQ443 JDQ443 + Tislelizumab JDQ443 + Trametinib Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments (KontRASt-R) Active, not recruiting ITA | FRA | ESP | DNK | CAN | BEL 4
NCT06625775 Phase I BBO-10203 + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin BBO-10203 + Trastuzumab BBO-10203 + Fulvestrant + Ribociclib BBO-10203 Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors Recruiting USA | FRA | ESP | BRA | AUS 1
NCT07808138 Phase II Cemiplimab RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer (RADICAL-IO) Not yet recruiting NLD 0
NCT06532032 Phase Ib/II Amivantamab-vmjw + Docetaxel A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer (swalloWTail) Completed USA | TUR | GBR 1
NCT03784378 Phase I RXDX-105 Continued Access to RXDX-105 Completed USA 0
NCT07322341 Phase II Atezolizumab + SX-682 SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer Recruiting USA 0
NCT05241873 Phase Ib/II BLU-451 (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations Terminated USA | CAN 3
NCT04683250 Phase Ib/II Vepafestinib Study of RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities (MARGARET) Recruiting USA | AUS 2
NCT05435846 Phase I Capmatinib + Trametinib Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation Terminated USA 0
NCT06094296 Phase II Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) Terminated USA | AUS 0
NCT04551521 Phase II Atezolizumab Atezolizumab + Ipatasertib Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Cobimetinib Alectinib Atezolizumab + Cobimetinib + Vemurafenib CRAFT: The NCT-PMO-1602 Phase II Trial Completed DEU 0
NCT03755102 Phase I Dacomitinib A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib. Completed USA 0
NCT04268550 Phase II Selpercatinib Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) Active, not recruiting USA 0
NCT04736173 Phase II Zimberelimab Carboplatin + Paclitaxel + Pemetrexed Disodium AB154 + Zimberelimab Pembrolizumab Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer (ARC-10) Completed USA | TUR 8
NCT04819100 Phase III Selpercatinib A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432) Active, not recruiting USA | TUR | SWE | ROU | POL | NOR | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS 11
NCT07234877 Phase II Carboplatin + Ivonescimab + Nab-paclitaxel Carboplatin + Ivonescimab + Pemetrexed Disodium Carboplatin + Ivonescimab + Paclitaxel Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets Not yet recruiting SVN | NLD | ITA | GRC | FRA | ESP | DEU | AUT 0
NCT03157128 Phase Ib/II Selpercatinib A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001) Active, not recruiting USA | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CHE | CAN | AUS 5
NCT04194944 Phase III Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Selpercatinib Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431) Active, not recruiting TUR | ROU | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG 9
NCT05845671 Phase Ib/II Amivantamab-vmjw Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations Active, not recruiting USA 0
NCT03334617 Phase II Danvatirsen + Durvalumab Durvalumab + Olaparib Cediranib + Durvalumab Ceralasertib Durvalumab + Vistusertib Durvalumab + Trastuzumab deruxtecan Ceralasertib + Durvalumab Durvalumab + Oleclumab Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON) Active, not recruiting USA | ISR | FRA | ESP | DEU | CAN | AUT 1
NCT05589818 Phase II Pembrolizumab Pembrolizumab for Advanced NSCLC and PS 2-3 Recruiting USA 0
NCT07784959 Phase I eCF506 + Lorlatinib Study of NXP900 With Lorlatinib in ALK+ Lung Cancer Recruiting USA 0
NCT04222972 Phase III Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Pralsetinib Cisplatin + Gemcitabine Carboplatin + Gemcitabine Cisplatin + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Terminated TUR | SWE | POL | NOR | NLD | ITA | IRL | GBR | FRA | ESP | DEU | CHE | BRA | BEL | AUS | ARG 6
NCT07017829 Phase II GT103 + Pembrolizumab GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer Recruiting USA 0
NCT05364645 Phase II Carboplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium + Selpercatinib Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer Withdrawn USA 0
NCT06758401 Phase III Pembrolizumab Pembrolizumab + SGN-B6A This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. (Be6A Lung-02) Recruiting USA | TUR | SVK | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG 8
NCT04940052 Phase III Dabrafenib + Trametinib Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer Active, not recruiting USA | TUR | CAN | BRA | ARG 6
NCT05671510 Phase III ONC-392 Docetaxel ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003) Active, not recruiting USA | TUR | NLD | ITA | GBR | ESP | DEU | CAN | BEL | AUS 2
NCT06364917 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC Recruiting USA 0
NCT07393555 Phase II Ivonescimab Sacituzumab govitecan-hziy Ivonescimab + Sacituzumab govitecan-hziy Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial) Recruiting USA 0
NCT07315113 Phase I eCF506 + Osimertinib Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer Recruiting USA 0
NCT05935774 Phase II Atezolizumab + Trabedersen OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer Withdrawn USA 0
NCT06458036 Phase II Selpercatinib Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE) (RAISE) Recruiting USA 0
NCT06822543 Phase II Carboplatin + Datopotamab deruxtecan + Pembrolizumab A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer) (TROPICAL-1) Recruiting BRA 0
NCT07222566 Phase III SSGJ-707 Pembrolizumab Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Recruiting USA | TUR | POL | ITA | ISR | HUN | GRC | FRA | ESP | DEU | CZE | CAN | BRA | AUS | ARG 5
NCT07715396 Phase III Pembrolizumab Carboplatin + Paclitaxel + Tislelizumab Tislelizumab Carboplatin + Nab-paclitaxel + Tislelizumab Carboplatin + Pemetrexed Disodium + Tislelizumab Cisplatin + Pemetrexed Disodium + Tislelizumab Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden (High Five) Not yet recruiting DEU 0
NCT06067776 Phase I Cetuximab + Osimertinib + Tucatinib Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer Unknown status USA 0
NCT05048797 Phase III Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Trastuzumab deruxtecan A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations Active, not recruiting USA | TUR | POL | NLD | ITA | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUT 7
NCT02314481 Phase II Vemurafenib Atezolizumab + Carboplatin + Paclitaxel Atezolizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Cisplatin + Pemetrexed Disodium Atezolizumab Alectinib Ado-trastuzumab emtansine Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWINII) Completed GBR 0
NCT05676749 Phase I Aldesleukin + C-TIL051 + Pembrolizumab C-TIL051 in Non-Small Cell Lung Cancer Terminated USA 0
NCT06448572 Phase Ib/II EXL01 + Nivolumab EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy. (EXLIBRIS) Recruiting FRA 0